Last month, we published an article that highlighted Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) as an attractive play on the cannabis and psychedelic extract market. Our thesis is based off the strength of the management team, the structure of the business, and the potential catalysts for…
In late December, Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) reported to have started to research the impact that muscimol has on a variety of ailments and we are impressed with how the story has advanced since then. Less than two weeks after Psyched announced that it started…
Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic therapeutics, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel to leverage its innovative technology, Kernel Flow, for its upcoming sponsored clinical work. Click here to view the accompanying film. Flow is a…
Numinus Wellness Inc. (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), announced today that it has signed a lab services agreement with Optimi Health Corp., developers of a vertically integrated functional mushroom brand focused…
Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds…
Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC, a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders. Entheon has…
Tryp Therapeutics Inc. is pleased to announce the successful closing of previously announced initial public offering of units. A total of 20,010,000 Units were sold, including 2,610,000 Units following the exercise in full by the Agent (as defined herein) of its over-allotment option, at a price of $0.25 per Unit…
Yesterday morning, Cybin Inc. (NEO:CYBN) reported a major milestone announcing the closing of 100% of Adelia Therapeutics Inc. The transaction is transformational for Cybin’s drug development program and we are favorable on the potential that is associated with the combined company. A Transformational All-Stock Acquisition for Cybin One of the…
So far this year, the psychedelic biotech market has been one of the most exciting emerging industries. Going forward, we do not expect this trend to change and believe that recent developments on both the regulatory and biotech side of the industry have only increased the amount of credibility that…
Tryp Therapeutics Inc. is pleased to announce that it has obtained a receipt for its final prospectus, which was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario on December 8, 2020 in connection with the initial public offering of 17,400,000 units of the…
